Company Intelligence Profile

Novocura Tech Health Services Private Limited

Novocura Tech Health Services Private Limited is the corporate entity behind mfine, an AI-enabled digital healthcare / telemedicine platform founded in 2017 by Prasad Kompalli and Ashutosh Lawania, offering instant doctor teleconsultations, at-home diagnostic lab tests, medicine delivery, dental/vision care and chroni…

CIN: U85100TN2017PTC166713ActiveRoC Chennai / Tamil Nadu

Last updated 10 August 2026

SummaryFrom public filings

Novocura Tech Health Services Private Limited operates the AI-enabled digital healthcare platform mfine, providing telemedicine services, at-home diagnostics, and more. Founded in 2017, it merged with LifeCell International's diagnostics business in 2022 to form LifeWell, supported by an $80M investment from OrbiMed. Financial reporting for FY2025 showed a 64% revenue decline, reflecting a post-merger restructuring.

Compiled from MCA filings and other public records. Figures may lag the latest filing; verify against the detailed sections below.

Unlock the full profile on AICA

Deeper analysis, financial signals and peer comparisons.

Book a demo

Company Identity

Registered nameNovocura Tech Health Services Private Limited
CINU85100TN2017PTC166713
PANAAFCN4953K
StatusActive
ListingUnlisted (private limited company; not listed on any stock exchange)
Incorporated16 February 2017
ROCRoC Chennai / Tamil Nadu
Sector (NIC)
  • Health and Social Work (Section Q)
  • NIC activity codes for "Other IT consulting services n.e.c." and "Other Hospital and Medical Care Activities" — consistent with an AI-enabled telehealth platform
Registered address
  • No.16, Vijayaraghava Road, I Lane, Thyagarayanagar (T Nagar), Chennai, Tamil Nadu 600017
  • Note: this exact address is also LifeCell International's corporate HQ — a strong corroborating signal for the group affiliation described below, not a data error
Authorized capital₹19.53 crore
Paid-up capital₹18.59 crore

Business Overview

  • Novocura Tech Health Services Private Limited is the corporate entity behind mfine, an AI-enabled digital healthcare / telemedicine platform founded in 2017 by Prasad Kompalli and Ashutosh Lawania, offering instant doctor teleconsultations, at-home diagnostic lab tests, medicine delivery, dental/vision care and chronic-disease-management programs to consumers and corporates (clients cited on mfine.co include Amazon, Honeywell, Nestlé, Uber, American Express)
  • In July 2022, mfine merged with LifeCell International's diagnostics business to form a combined entity (reported as "LifeWell"), with OrbiMed investing $80M in the merged unit
  • This explains the shared registered address with LifeCell International and the multiple common-director links to LifeCell-group entities found on Tofler (LifeCell International, LifeWell Diagnostics, Cellutions Biostorage, H S Pathology, Creative Art Concepts, Abusha Estates, Amuda Capital Services LLP)
  • Financial filings for FY2025 show a sharp (~64%) YoY revenue decline and near-elimination of borrowings/net-worth, consistent with a post-merger wind-down/restructuring of the standalone mfine legal entity rather than a going-concern operating business at prior scale
  • Confidence: medium — the merger narrative is corroborated by two independent aggregator/press mentions but full primary-filing confirmation was not obtained

Directors

Confirmed from Tofler/TheCompanyCheck (2 sources agree on names, DINs only partially sourced):

NameDINRoleAppointed
Ashutosh Lawania01295011Director16-Feb-2017

Financials

SummaryFrom public filings

Novocura Tech Health Services experienced a significant drop in revenue to ₹18.85 crore in FY2025, down approximately 64% year-on-year, with borrowings eliminated and total assets reducing by about 85%. Despite these declines, the company achieved an impressive operating margin of 98.46% and a net profit margin of 4.12%.

  • FY2025 (audited, standalone, year ending March 2025) — TheCompanyCheck: Revenue ₹18.85 crore (down ~64% YoY)
  • Tofler (same filing): revenue bracket "₹10-25 crore", borrowings down 100% (eliminated), total assets down ~85%, book net worth down ~238% (i.e., swung deeply negative), operating margin 98.46%, net profit margin 4.12%, gross margin 0.08%, ROCE 225.75%, debt-to-equity 1.18
  • EBITDA and absolute PAT/net-worth/borrowings figures are paywalled on both aggregators — not obtained as exact values
  • Two sources agree directionally (large YoY decline) — confirmed trend, unconfirmed exact absolute figures
  • This pattern is consistent with the July 2022 mfine/LifeCell merger reshaping the standalone entity's books; standalone vs. consolidated treatment for the merged "LifeWell" entity is unclear and not separately confirmed

Funding

Funding raised is attributed to the mfine brand/business (pre-merger), not confirmed as filed directly against this CIN in primary MCA records:

Series A, May 2018$4.2M
Series B$17.2M, lead SBI Investment (Japan), with SBI Ven Capital, Beenext, Stellaris Venture Partners, Prime Venture Partners
Later round, 31-May-2021$48M, led by Beenext, with SBI Group Japan, Stellaris Venture Partners, Heritas Capital, SBI Ven Capital Singapore, Y's Investment, Prime Venture Partners, Alteria Capital
Total raisedTracxn and TheCompanyCheck agree on ~$87.7M across 9 rounds/30 investors. Inc42 Datalabs reportedly shows "$592.99M+" — this figure is a strong outlier and very likely conflates mfine with the larger combined LifeCell/LifeWell group's cumulative funding (an entity-confusion risk flagged per house rules); NOT used as the headline number
Post-mergerOrbiMed invested $80M into the combined mfine+LifeCell diagnostics entity ("LifeWell") in/around July 2022 — this capital sits at the merged-entity level, not confirmed as booked directly under this CIN

Tracxn used here only for round names/amounts per house rules, cross-checked against press (Inventiva, AsiaTechDaily, Entrackr).

Charges/Loans

  • 0 open charges
  • 3 satisfied charges totaling ₹46 crore — ₹6 crore (10-Oct-2018), ₹25 crore (14-Jun-2019), ₹15 crore (21-Jan-2021), all marked satisfied
  • TheCompanyCheck corroborates "no registered (open) charges." Confirmed

Competitors

MediBuddy
scale: large, well-funded telehealth leader, reportedly larger revenue base
Practo
scale: large, pan-India doctor-discovery + teleconsult platform
Tata 1mg
scale: large, backed by Tata Digital, pharmacy+diagnostics+teleconsult
Apollo 24|7
scale: large, hospital-network-backed super-app
DocsApp
scale: mid, teleconsultation-focused (subsequently folded into MediBuddy)
Practika/other regional telehealth apps
scale: small-mid. mfine itself, post-2022 merger, is best understood as a shrinking/niche player relative to…

Frequently Asked Questions

What does Novocura Tech Health Services Private Limited do?
Novocura Tech Health Services Private Limited is the corporate entity behind mfine, an AI-enabled digital healthcare / telemedicine platform founded in 2017 by Prasad Kompalli and Ashutosh Lawania, offering instant doctor teleconsultations, at-home diagnostic lab tests, medicine delivery, dental/vision care and chroni…
What is the CIN of Novocura Tech Health Services Private Limited?
The Corporate Identification Number (CIN) of Novocura Tech Health Services Private Limited is U85100TN2017PTC166713.
Where is Novocura Tech Health Services Private Limited registered?
Novocura Tech Health Services Private Limited is registered with RoC Chennai / Tamil Nadu (sources disagree slightly on label: Tofler says "Tamil Nadu", TheCompanyCheck says "Chennai" - same RoC office, confirmed). Registered address: No.16, Vijayaraghava Road, I Lane, Thyagarayanagar (T Nagar), Chennai, Tamil Nadu 600017 (sources: Tofler, TheCompanyCheck).
When was Novocura Tech Health Services Private Limited incorporated?
Novocura Tech Health Services Private Limited was incorporated on 16 February 2017 (source: Tofler, TheCompanyCheck).

Explore on Recur Club

Bharat Ke Super Founders

Recur Club's show spotlighting the founders building India's next generation of companies. Watch their stories.

Watch the show

Looking for business funding?

Recur Club is India's largest AI-native debt platform - working capital, term loans and structured debt from 150+ lending partners, without diluting equity.

Disclaimer: Company information shown on this page is compiled from public records and third-party sources. It may be incomplete, outdated, or contain inaccuracies, and is provided for general informational purposes only. Please verify details independently before relying on them.